Precision Neuroscience has raised $250 million in an oversubscribed Series D financing, bringing its total funding to $430 million as it advances its brain-computer interface technology toward broader clinical use and commercialization. The round was co-led by Pershing Square Inc., the Ackman Oxman Institute, and an undisclosed life sciences investment fund. Additional investors included Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures, and JSL Health Capital.
Founded in 2021, Precision develops brain-computer interface technology intended to establish a communication pathway between the human brain and external computing systems.
Its principal technology, the Layer 7 Cortical Interface, is designed to collect high-resolution neural signals while minimizing the invasiveness of implantation.
Precision describes the device as minimally invasive, safely removable, and capable of high-bandwidth neural recording.
The company is developing the technology with the goal of helping people living with neurological injuries and other conditions that impair movement or communication.
The latest financing will support the expansion of Precision’s clinical development program, continued regulatory work, and the infrastructure required for future commercialization.
The funding follows several milestones across the company’s clinical research, manufacturing, and commercial development activities.
Precision reports completing more than 100 patient procedures across 18 major medical institutions.
Its clinical network includes the Perelman School of Medicine at the University of Pennsylvania, University of Chicago Medicine, Mount Sinai Health System, and West Virginia University’s Rockefeller Neuroscience Institute.
These relationships support the company’s evaluation of its technology in clinical environments and provide access to neurosurgeons and researchers working on brain-computer interface applications.
Precision has also received FDA clearance for its Layer 7 Cortical Interface.
The company intends to use the Series D capital to advance the technology through subsequent stages of FDA review and support additional clinical development.
The existing clearance is an important regulatory milestone, although it should not be interpreted as establishing approval for every potential future clinical application of the technology.
Precision has also demonstrated high-resolution neural recording across 4,096 electrodes, alongside real-time decoding of intended movement.
These capabilities form part of the company’s effort to translate neural activity into signals that can be interpreted by external computing systems.
Its research activities include peer-reviewed work published in Nature Biomedical Engineering and clinical research conducted with Johns Hopkins University.
Researchers at the University of Pennsylvania have also used recordings from Layer 7 to develop a more detailed map of the human motor cortex.
Beyond its clinical research program, Precision has established a commercial partnership with Medtronic to integrate its technology with an established neurosurgical platform.
The relationship is intended to support the development and potential adoption of its brain-computer interface technology within existing neurosurgical workflows.
Precision has also invested in manufacturing infrastructure.
The company operates a wholly owned microelectromechanical systems manufacturing facility in Texas, providing control over the production of its specialized electrode arrays.
The facility is part of Precision’s strategy to develop an integrated manufacturing and supply chain infrastructure capable of supporting future commercial production.
The company also recently appointed Dr. John Donoghue, founder of BrainGate and a 2026 Queen Elizabeth Prize for Engineering laureate, as a Scientific Advisor.
His appointment adds experience in neuroscience and brain-computer interface research as Precision expands its clinical and technology development activities.
The new financing provides substantial resources for Precision’s next stage of growth, including additional clinical procedures, regulatory advancement, product development, and manufacturing scale-up.
KEY QUOTES:
“The next phase of BCI will be defined by more than technology alone. We have built the clinical network, regulatory position, and manufacturing base that leadership in this field requires. We are also putting safety at the center of our product design, forming deep partnerships with the world’s leading neurosurgeons and academic medical centers, and building a company and a culture that we hope will endure. We’re proud to have investors who share that long-term vision.”
Michael Mager, Co-Founder And CEO Of Precision Neuroscience
“We have learned that the brain can recover from even catastrophic injury, and that there is far more that can be done for people living with neurological injuries. Neurotechnology will be central to the next generation of cures, treatments, and rehabilitation. It will also produce some of the most important and valuable companies of our time that will improve the lives of millions of people. Precision has the team, technology, and ambition to be a leader in BCI, and we are therefore delighted to invest in the company.”
Bill Ackman, CEO Of Pershing Square And Co-Founder Of The Ackman Oxman Institute
